Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Unknown | 2 |
ASO | 2 |
Oligonucleotide | 1 |
Top 5 Target | Count |
---|---|
ANGPTL4(angiopoietin like 4) | 3 |
Target |
Mechanism ANGPTL4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Jul 2024 |
Sponsor / Collaborator |
Start Date17 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lipisense ( ANGPTL4 ) | Hypertriglyceridemia More | Phase 1 |
Lipodystrophy(Lipigon Pharmaceuticals) | Lipodystrophy More | Phase 1 |
ARDS treatment (Lipigon) ( ANGPTL4 ) | Respiratory Distress Syndrome, Acute More | Preclinical |
Dyslipidemia(Lipigon Pharmaceuticals) | Dyslipidemias More | Preclinical |
P4 CAP (Lipigon Pharmaceuticals) ( ANGPTL4 ) | Community Acquired Pneumonia More | Discovery |